Form 4: Director Lori Kunkel Sells Enliven Therapeutics Shares

Enliven Therapeutics Director Lori Kunkel sold 10,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Lori Kunkel sold a total of 10,000 shares of Enliven Therapeutics (ELVN) common stock on June 5, 2026.
• The sales were executed in three tranches at weighted average prices of $34.2794, $35.3573, and $35.8187 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
• Following these transactions, the reporting person retains direct ownership of 51,884 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned 10b5-1 program, which is standard practice for directors.

Positives

• The sale was executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the direct equity stake held by a member of the Board of Directors.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the current valuation of the company.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, often used by executives and directors to manage personal liquidity without signaling changes in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to ensure compliance with SEC regulations while liquidating equity positions.

Related Party Transactions

• The filing notes the transfer of 31,172 shares from the Lori Kunkel Revocable Trust to the reporting person.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the director's total interest.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Insider Trading, Form 4, Biotech, Director Sale